https://www.mediresonline.org/

ISSN: 2836-497X

Open Access

Archives of Gynaecology and Women Health

Editorial Letter

Synergistic Potential of Nutraceuticals in Female Sexual Dysfunction: A Mechanistic Rationale and Proposed Translational Research Program

Raouf Roshdy[1]* Doaa Saleh[2]

[1]Department of Obstetrics and Gynecology, Egypt Health Foundation, Cairo University, Egypt.
[2]Department of Obstetrics and Gynecology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.

***Corresponding Author:** Raouf Roshdy, Department of Obstetrics and Gynecology, Egypt Health Foundation, Cairo University, Egypt.

Received Date: 04 June 2026; **Accepted Date:** 01 July 2026; **Published Date:** 15 July 2026

Abstract

Background: Female Sexual Dysfunction (FSD) is a multifactorial condition reported to affect a substantial proportion of women, with limited approved therapeutic options.

Proposal: This paper proposes a hypothesis-driven, over-the-counter nutraceutical combination intended to address several proposed mechanisms relevant to FSD, and outlines a translational research pathway in silico, preclinical, and Phase II clinical to test that hypothesis. No combined formulation of these eight ingredients has been tested to date; the synergy described here is a research hypothesis, not an established finding.

Methods: A narrative review identified eight nutraceuticals with individual-ingredient evidence plausibly relevant to FSD mechanisms: Resveratrol, Ashwagandha, Tribulus terrestris, L-Arginine, Black Cohosh, Evening Primrose Oil, Shilajit, and Visnadine. Proposed outcomes: If the proposed research program is carried out, it may clarify whether combined administration affects vasodilation, hormonal measures, oxidative stress markers, and patient-reported sexual function outcomes. These are hypothesized endpoints, not demonstrated results.

Conclusion: A multi-mechanism nutraceutical approach to FSD is a reasonable hypothesis worth testing given the individual-ingredient evidence base, but currently rests on inference from single-ingredient studies rather than combination data.

Key words: Female Sexual Dysfunction (FSD), Hypoactive Sexual Desire Disorder (HSDD), Female Sexual Arousal Disorder (FSAD), Female Orgasmic Disorder (FOD).

Introduction

Female Sexual Dysfunction: Overview

Female Sexual Dysfunction (FSD) encompasses a spectrum of conditions, including:

- Hypoactive Sexual Desire Disorder (HSDD)
- Female Sexual Arousal Disorder (FSAD)
- Female Orgasmic Disorder (FOD)

Current Treatment Landscape

Existing pharmacological interventions are commonly characterized by:

- A limited number of FDA-approved options
- Reported side effects such as nausea and hypotension
- Accessibility and adherence challenges for some patients

Nutraceutical Rationale

Nutraceuticals are proposed here as a complementary avenue worth investigating, on the basis that they may offer:

- Multi-mechanistic biological activity, based on individual-ingredient studies
- A generally-reported favorable safety profile relative to some prescription options, though this has not been tested for this combination
- Over-the-counter accessibility

2. Nutraceutical Selection and Mechanistic Rationale

Nutraceutical	Proposed Mechanism	Supporting Source (verified)
Resveratrol	Estrogen-receptor binding; increases nitric oxide bioavailability and endothelium-dependent vasodilation	Evans, Howe & Wong (2017), Nutrients 9(1):27 —cerebrovascular/cognitive outcomes in post-menopausal women. Direct effect on genital blood flow or sexual function was not measured in this trial [Inference: mechanism may extend to genital vasculature, not confirmed].
Ashwagandha	Adaptogenic HPA-axis modulation;reduces cortisol	Chandrasekhar et al. (2012), Indian J Psychol Med 34(3):255–262. Measured stress/anxiety and cortisol; did not measure libido or sexual function directly [Inference for relevance to FSD].
Tribulus terrestris	Reported modulation of androgen pathways; proposed nitric-oxide-mediated vasodilation	Akhtari et al. (2014), DARU J Pharm Sci 22:40. Randomized trial in women with hypoactive sexual desire disorder; reported improvement in FSFI domains including desire and lubrication.
L-Arginine	Nitric oxide precursor; proposed improvement in genital blood flow	Cieri-Hutcherson et al. (2021), Pharmacy (Basel) 9(2):71. Systematic review of L-arginine (alone and in combination) for HSDD-related conditions in women.
Black Cohosh	Phytoestrogenic activity; proposed serotonergic modulation	Shams et al. (2010), Altern Ther Health Med 16(1):36–44. Meta-analysis of vasomotor (hot flash) symptom reduction; arousal or sexual-function outcomes were not the measured endpoint [Inference for relevance to FSD].
Evening Primrose Oil	Gamma-linolenic acid; proposed anti-inflammatory, prostaglandin-pathway effect	Farzaneh et al. (2013), Arch Gynecol Obstet 288(5):1075–1079. Randomized trial measuring menopausal hot-flash frequency/severity; dyspareunia or sexual function were not the measured endpoint [Inference for relevance to FSD].
Shilajit	Fulvic-acid-associated antioxidant activity	Pingali & Nutalapati (2022), Phytomedicine 105:154334. Randomized trial on bone mineral density, oxidative stress, and inflammation in post-menopausal women with osteopenia; sexual function was not assessed [Inference for relevance to FSD].
Visnadine	Calcium-channel-mediated vasodilation; proposed increase in genital blood flow	Caruso et al. (2018), Gynecol Endocrinol 34(2):110–114. Randomized crossover trial in women with female sexual arousal disorder; reported improved FSFI scores and Doppler-measured clitoral blood flow.

Table 1: summarizes the eight candidate ingredients, their proposed mechanisms, and the supporting source identified for each, following independent verification of each citation.

Proposed Synergistic Rationale [Speculation — not tested as a combination]

Vasodilation pathway: L-Arginine + Resveratrol + Visnadine hypothesized to support genital blood flow

Hormonal/stress pathway: Ashwagandha (cortisol) + Black Cohosh (phytoestrogenic activity) hypothesized to support desire and reduce discomfort

Antioxidant pathway: Evening Primrose Oil + Shilajit hypothesized to reduce oxidative stress markers

Androgen/energy pathway: Tribulus + Shilajit hypothe-

sized to support subjective energy and arousal

Proposed Combined Mechanism	Hypothesized Outcome [Speculation — combination untested]
Vasodilation (L-Arginine + Visnadine + Resveratrol)	Improved genital blood flow, which may support arousal
Cortisol modulation (Ashwagandha)	Reduced stress, which may support desire
Phytoestrogenic activity (Black Cohosh)	Hormonal balance, which may reduce discomfort during intercourse

Table 2: Proposed Pathway Integration

3. Research Hypothesis

Hypothesis: a combination of the ingredients above may improve FSD-related symptoms via one or more of the following mechanisms, relative to placebo:

- Increased genital blood flow
- Changes in sex hormone and stress hormone measures
- Reduced oxidative stress markers
- Changes in neurotransmitter-linked subjective measures (desire, arousal)

This is a hypothesis to be tested, not a demonstrated effect of the combination.

4. Proposed Methodology

1. Preliminary Investigations

i) In silico phase:

- Molecular docking studies
- Systems-biology pathway modeling

ii) Preclinical studies:

- In vitro mechanism validation
- Ovariectomized rat model investigations

2. Proposed Clinical Trial Design

Proposed Phase II trial parameters:

- Double-blind, placebo-controlled design
- 12-week duration
- Approximately 200 participants (to be confirmed by a formal power calculation)
- Outcome measures:Female Sexual Function Index (FSFI) scores, hormonal panels, patient-reported outcomes

5. Anticipated Outcomes and Significance

1. Primary Outcomes (hypothesized, not observed)

- A meaningful improvement in FSFI scores, magnitude to be determined by the trial rather than assumed in advance
- Change in oxidative stress markers
- Change in relevant hormonal measures

2. Potential Public Health Relevance

- Addresses a condition reported to affect a substantial share of women, pending confirmation of the specific prevalence figure used
- May reduce some access barriers associated with prescription-only treatments, if shown safe and effective
- Would offer an additional option alongside, not a replacement for, existing clinical care

6. Challenges and Limitations

1. Bioavailability:

- Nano-encapsulation and dosage optimization may be needed to reach physiologically relevant tissue concentrations

2. Study limitations:

- Individual variability in response
- FSD is a multifactorial condition; a single formulation is unlikely to address every contributing cause
- No combination data yet exist for these eight ingredients together; single-ingredient evidence does not establish combined efficacy or safety
- Several of the source studies used here measured outcomes (bone density, cortisol, hot flashes) other than sexual function directly, which limits how directly they support FSD-specific claims

Conclusion

This proposal outlines a multi-mechanism nutraceutical strategy for FSD, grounded in individual-ingredient evidence of varying strength and directness. Whether the combination improves FSD outcomes, and whether it does so more safely or effectively than existing options, has not been tested and

should be treated as an open research question rather than a settled conclusion.

References

1. Evans, Hamish M., Peter RC Howe, and Rachel HX Wong. "Effects of resveratrol on cognitive performance, mood and cerebrovascular function in post-menopausal women; a 14-week randomised placebo-controlled intervention trial." Nutrients 9, no. 1 (2017): 27.
2. Chandrasekhar, Kartik, Jyoti Kapoor, and Sridhar Anishetty. "A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults." *Indian journal of psychological medicine* 34, no. 3 (2012): 255-262.
3. Akhtari, Elham, Firoozeh Raisi, Mansoor Keshavarz, Hamed Hosseini, Farnaz Sohrabvand, Soodabeh Bioos, Mohammad Kamalinejad, and Ali Ghobadi. "Tribulus terrestris for treatment of sexual dysfunction in women: randomized double-blind placebo-controlled study." *DARU Journal of Pharmaceutical Sciences* 22, no. 1 (2014): 1-7.
4. Cieri-Hutcherson, Nicole E., Andrea Jaenecke, Ajeet Bahia, Debra Lucas, Ann Oluloro, Lora Stimmel, and Timothy C. Hutcherson. "Systematic review of L-arginine for the treatment of hypoactive sexual desire disorder and related conditions in women." Pharmacy 9, no. 2 (2021): 71.
5. Shams, Taghreed, Maninder Singh Setia, Robert Hemmings, Jane McCusker, Maida Sewitch, and Antonio Ciampi. "Efficacy of black cohosh-containing preparations on menopausal symptoms: a meta-analysis." *Alternative Therapies in Health & Medicine* 16, no. 1 (2010): 36.
6. Farzaneh, Farah, Setareh Fatehi, Mohammad-Reza Sohrabi, and Kamyab Alizadeh. "The effect of oral evening primrose oil on menopausal hot flashes: a randomized clinical trial." *Archives of gynecology and obstetrics* 288, no. 5 (2013): 1075-1079.
7. Pingali, Usharani, and Chandrasekhar Nutalapati. "Shilajit extract reduces oxidative stress, inflammation, and bone loss to dose-dependently preserve bone mineral density in postmenopausal women with osteopenia: A randomized, double-blind, placebo-controlled trial." Phytomedicine 105 (2022): 154334.
8. Caruso, Salvatore, Diletta Mauro, Maria Cariola, Valentina Fava, Agnese Maria Chiara Rapisarda, and Antonio Cianci. "Randomized crossover study investigating daily versus on-demand vulvar Visnadine spray in women affected by female sexual arousal disorder." *Gynecological Endocrinology* 34, no. 2 (2018): 110-114.

Citation: Raouf Roshdy, Doaa Saleh, Synergistic Potential of Nutraceuticals in Female Sexual Dysfunction:A Mechanistic Rationale and Proposed Translational Research Program, *Arch. Gynaecol. Women. Health.* Vol. 5 Iss. 1. (2026) DOI:10.58489/2836-497X/035